Metabolomic profiling in colorectal cancer: opportunities for personalized medicine. (September 2013)

• Record Type: Journal Article
• Authors: Zheng, Xiaojiao; Xie, Guoxiang; Jia, Wei
• Is Part Of: Personalized medicine. Volume 10:Number 7(Year 2013)
• Page Start: 741
• Page End: 755
• Publication Date: 2013-09
• Subjects: biomarkers -- colorectal cancer -- drug discovery -- early diagnosis -- metabolomic profiling -- personalized medicine -- staging -- treatment; Pharmacogenomics -- Periodicals; Pharmacogenetics -- Periodicals; 615.19
• DOI: 10.2217/pme.13.73
• Languages: English
• ISSNs: 1741-0541

Abstract

Colorectal cancer (CRC) is one of the most common types of cancer in the world, with high prevalence and mortality. Understanding the alterations of cancer metabolism and identifying reliable biomarkers would facilitate the development of novel technologies of CRC screening and early diagnosis, as well as new approaches to providing personalized medicine. Metabolomics, as an emerging molecular phenotyping approach, provides a clinical platform technology with an unprecedented amount of metabolic readout information, which is ideal for theranostic biomarker discovery. Metabolic signatures can link the unique pathophysiological states of patients to personalized health monitoring and intervention strategies. This article presents an overview of the metabolomic studies of CRC with a focus on recent advances in the biomarker discovery in serum, urine, fecal water and tissue samples for cancer diagnosis. The development and application of metabolomics towards personalized medicine, including early diagnosis, cancer staging, treatment and drug discovery are also discussed.